Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

PR NewswireNov 7 19:50

Protalix BioTherapeutics To Present Data From Phase I Clinical Trial Of PRX-115 Recombinant PEGylated Uricase Product Candidate

BenzingaOct 25 19:19

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

PR NewswireOct 25 19:18

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

PR NewswireSep 4 18:50

Protalix BioTherapeutics Announced That It Has Repaid In Full Its 7.50% Senior Secured Convertible Promissory Notes Financed Entirely With Available Cash

BenzingaSep 3 18:51

Is Protalix BioTherapeutics, Inc. (PLX) The Best Rated Penny Stock To Buy According to Analysts?

Yahoo FinanceAug 30 20:38